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Tautomycin inhibited the catalytic subunits of protein phosphatase-1 (4 = 0.16 nM) more potently than protein phosphatase 2A (K, = 0.4 nM), 
and the native forms of these enzymes in mammalian, protozoan and $mt extracts were inhibited in a similar manner. Protein phziphatase 2B 
was inhibited IOOOO-fold less potently, while two other phosphatases and six protein kinases were unaffected at 10 PM. Okadaic acid prevented 
the binding of tautomycin to protein phosphatase 2A, indicating a common binding site for both inhibitors. The different relative potencies of 
tautomycin and okadaic acid for protein phosphatases 1and 2A suggest hat parallel use of both inhibitors may help to identify physiological 
substrates for each enzyme. 
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1. INTRODUCTION 
Over the past few years two potent toxins produced 
by aquatic microorganisms have been shown to exert 
their effects by inhibiting protein phosphatases 1 and 
2A (PPI, PP2A), two of the major protein serine/ 
threonine phosphatases of eukaryotic cells. The first is 
okadaic acid [l], a fatty acyl polyketide produced by 
marine dinoflagelates which accumulates by filter 
feeding in the digestive glands of molluscs and marine 
sponges, such as Halichondria okadaii from which it 
was first extracted. It is a potent tumour promoter and 
one of the causative agents of diarrhetic seafood poi- 
soning (reviewed in [2]). The second is microcystin-LR, 
a cyclic heptapeptide produced by certain species of the 
cyanobacteria Microcystis, Oscillatoria and Anabaena, 
which is a potent hepatotoxin [3,4]. Although both 
compounds have quite different chemical composi- 
tions, their binding to PPl and PP2A is mutually ex- 
clusive, suggesting that they may interact at the same 
site on each enzyme [3]. Similarly, interaction of PPl 
with the small thermostable proteins that inhibit this en- 
zyme specifically, inhibitors 1 and 2, prevents the subse- 
quent binding of microcystin-LR [3]. Thus all known 
substances that are potent inhibitors of PPl and/or 
PP2A may exert their effects by binding to the same 
sites on these enzymes. The sensitivity of PPl and 
PP2A to okadaic acid and microcystin-LR has been 
remarkably conserved and is virtually identical in eu- 
karyotes as diverse as mammals, yeast and higher plants 
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The soil bacteria Streptomyces make a vast array of 
structurally diverse compounds, some of which bear a 
resemblance to okadaic acid and microcystin. Many are 
polyketides (e.g. [7]) while others are peptides which, 
like microcystin, may contain both D- and L-amino 
acids and linkages other than cu,m-peptide bonds 
(reviewed in [S]). Recently, a polyketide called tauto- 
mycin, produced by Streptomyces griseochromogenes 
and Streptomyces verticillatus, was purified and 
characterised [9]. When drawn following its structural 
formula, the backbone of tautomycin matches that of 
okadaic acid in the region from carbon-l to carbon-16 
(Fig. 1). Moreover, some reported effects of tauto- 
mycin on cells are similar to those produced by okadaic 
acid. For example, tautomycin is toxic to all eukaryotic 
cells tested [lo] and rapidly induces bleb formation on 
the surface of human chronic leukemia cells, similar to 
those induced by phorbol dibutyrate [l 11. Tautomycin, 
like okadaic acid, does not compete with tumour-pro- 
moting phorbol esters for binding to cells, and does not 
activate protein kinase C significantly in vitro [ll]. 
Taken together these observations uggested that tauto- 
mycin, like okadaic acid, might be a protein phospha- 
tase inhibitor. In this paper we show that tautomycin is 
indeed a potent inhibitor of PPl and PP2A and that 
tautomycin and okadaic acid compete for binding to 
PP2A. However, unlike okadaic acid and microcystin, 
tautomycin has a higher affinity for PPl than PP2A. 
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Fig. 1. Structural formulae of tautomycin and okadaic acid. 
2. MATERIALS AND METHODS 
Tautomycin, a kind gift from Dr K. Isono (Antibiotics Labo- 
ratory, Institute of Physical and Chemical Research, Saitama, 
Japan), was dissolved in dimethyl sulphoxide to give a 5 mM solution 
and further diluted in aqueous buffers before use. Okadaic acid was 
generously provided by Dr Y. Tsukitani (Fujisawa Pharmaceutical 
Co., Japan). Other materials and methods were identical to those 
described in [3]. 
3. RESULTS AND DISCUSSION 
The dephosphorylation of glycogen phosphorylase 
(10 PM) by the purified catalytic subunits of PPl and 
PP2A from rabbit skeletal muscle was potently in- 
hibited by tautomycin. In the standard assay PPl and 
PP2A were completely inhibited at 3 nM and 30 nM, 
respectively. PP2B was inhibited over lOOOO-fold less 
strongly, while PP2C was not inhibited at all (Fig. 2). 
Since the concentrations of tautomycin required for in- 
hibition were similar to those of PPl and PP2A in the 
assays, ICSO values were determined over a range of 
phosphatase concentrations. These experiments gave 
apparent Ki values of 0.16 nM and 0.4 nM for inhibi- 
tion of PPl and PP2A, respectively, after extrapolation 
to infinite dilution of enzyme (Fig. 3). 
The specificity of tautomycin was examined further 
by testing its ability to inhibit other protein phospha- 
tases and protein kinases. The tautomycin (10 PM) was 
without effect on calf intestinal and potato acid phos- 
phatases, cyclic AMP-dependent protein kinase, pro- 
tein kinase C, the AMP-activated protein kinase, casein 
kinase- 1, casein kinase-2 and glycogen synthase 
kinase-3. 
The specificity of tautomycin for PPl and PP2A, but 
not PP2B or PP2C, was similar to okadaic acid and 
microcystin-LR and apparent Ki values extrapolated to 
infinite dilution are compared in Table I. Although all 
three inhibitors were effective in the nanomolar or sub- 
nanomolar range, tautomycin inhibited PPl more 
strongly than PP2A, whereas the reverse was true for 
okadaic acid and microcystin. 
We have shown previously that the binding of 
okadaic acid to PP2A prevents the subsequent binding 
of microcystin to PP2A [3] and the same experiments 
were employed to demonstrate that the binding of 
tautomycin and okadaic acid to PP2A are also mutually 
exclusive. Thus, the inhibition of PPl by tautomycin 
was examined in the presence of PP2A that had first 
been inactivated by incubation with NaF and PPi (see 
legend to Fig. 4). This caused an increase in the ICSO for 
tautomycin inhibition of PPl, implying that PP2A, 
although inactive, could nevertheless compete with PPl 
for tautomycin under these assay conditions. However, 
the increase in IGo was abolished by preincubating in- 
active PP2A with okadaic acid (Fig. 4), using a concen- 
tration in the assay (1.5 nM) sufficient to form a com- 
plex with PP2A, but too low to cause significant inac- 
tivation of PPl [12]. These experiments demonstrated 
that the binding of okadaic acid to PP2A prevented the 
subsequent binding of tautomycin. 
The catalytic subunits of PPl and PP2A are com- 
plexed to regulatory and/or targetting subunits in vivo 
[ 131. The active forms of PPl and PP2A present in 
dilute extracts of rat liver or Brassica napus (rape) seeds 
were also strongly inhibited by tautomycin (data not 
shown). However, when diluted to the same activities 
(0.06-0.08 mu/ml in the assays), the ICSO values were 
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Fig. 2. Inhibition of different protein phosphatases by tautomycin. The catalytic subunits of PPl (0) and PPZA (0) from rabbit skeletal muscle 
were both assayed at 0.24 mu/ml, respectively, using ‘ZP-labelled glycogen phosphorylase as substrate, PPZB from bovine brain (A) at 0.05 
mu/ml using “P-1abelled phosphorylase kinase and PP2C from rabbit skeletal muscle (A) at 0.035 mu/ml using “P-1abelled casein. For details 
of the assays and definition of enzyme units see [3]. 
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Fig. 3. Effect of protein phosphatase concentrations on inhibition by 
tautomycin. PPl (0) and two different preparations of PP2A (0, A). 
2-4-fold higher than those observed with the free 
catalytic subunits (Fig. 3). This is probably explained 
by the presence of regulatory/targeting subunits which 
suppress catalytic activity [ 131. Thus the molar concen- 
trations of the native forms of PPl and PP2A in the 
assays will be higher than the catalytic subunits and 
therefore require higher concentrations of tautomycin 
for inhibition. Similar observations have been made for 
microcystin-LR [3]. 
Tautomycin inhibited PPl purified from the ciliary 
membranes of the protozoan Paramecium tetraurelia 
[14] with an ICso value of 2 nM. However, like 
microcystin and okadaic acid [3,14], tautomycin failed 
to inhibit the PP2A-like enzymes of Paramecium and 
did not inhibit Paramecium PP2C. 
After these studies had been completed, we learned 
that Isono and coworkers have found that tautomycin 
competes with okadaic acid for binding to a particulate 
fraction prepared from mouse brain. They have also 
shown that tautomycin inhibits (I(&= 2.5 nM) the 
dephosphorylation of histone by a partially purified 
protein phosphatase preparation from mouse brain 
(presumably PPI, PP2A, or a mixture of these en- 
Table I 
Apparent Ki values for inhibition of protein phosphatases 1and 2A 
by tautomycin, okadaic acid and microcystin-LR 
Apparent Ki (nM) 
Tautomycin 
Okadaic acid 
Microcystin-LR 
PPl PPZA 
0.16 0.4 
10 -0.03 
0.06 <O.Ol 
Apparent Ki values were calculated by extrapolating plots of I& 
against mu/ml to zero phosphatase concentration. Apparent Ki 
values were calculated from the data in Fig. 3 (tautomycin) [12] 
(okadaic acid) and [3] (microcystin-LR). Assays were performed at a 
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